NRx Pharmaceuticals, Inc. (NRXP)
NASDAQ: NRXP · Real-Time Price · USD
1.790
-0.080 (-4.28%)
At close: Apr 4, 2025, 4:00 PM
1.855
+0.065 (3.65%)
After-hours: Apr 4, 2025, 7:52 PM EDT

NRx Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Selling, General & Admin
13.5114.2227.3174.9411.44
Upgrade
Research & Development
6.213.3717.0320.2610.63
Upgrade
Other Operating Expenses
----0.77-10.16
Upgrade
Operating Expenses
19.727.5944.3494.4311.9
Upgrade
Operating Income
-19.7-27.59-44.34-94.43-11.9
Upgrade
Interest Expense
-0.23-0.12--0.02-0.06
Upgrade
Interest & Investment Income
0.040.490.25--
Upgrade
Other Non Operating Income (Expenses)
-3.780.020.261.69-0.03
Upgrade
EBT Excluding Unusual Items
-23.67-27.19-43.83-92.76-11.98
Upgrade
Other Unusual Items
-1.45-2.964.08-0.31-39.79
Upgrade
Pretax Income
-25.13-30.15-39.75-93.06-51.78
Upgrade
Net Income
-25.13-30.15-39.75-93.06-51.78
Upgrade
Preferred Dividends & Other Adjustments
-0.01---
Upgrade
Net Income to Common
-25.13-30.16-39.75-93.06-51.78
Upgrade
Shares Outstanding (Basic)
118753
Upgrade
Shares Outstanding (Diluted)
118753
Upgrade
Shares Change (YoY)
40.50%15.20%40.17%36.90%220.58%
Upgrade
EPS (Basic)
-2.36-3.98-6.04-19.84-15.11
Upgrade
EPS (Diluted)
-2.36-3.98-6.04-74.40-15.11
Upgrade
Free Cash Flow
-10.64-21.66-39.77-37.71-2.27
Upgrade
Free Cash Flow Per Share
-1.00-2.86-6.05-8.04-0.66
Upgrade
EBITDA
-19.7-27.58-44.33-94.43-11.9
Upgrade
D&A For EBITDA
0.010.01000
Upgrade
EBIT
-19.7-27.59-44.34-94.43-11.9
Upgrade
Updated Mar 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q